Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Adrenocortical Carcinoma – Pipeline Review, H2 2016,
provides comprehensive information on the therapeutics under development for Adrenocortical Carcinoma (Oncology), complete with
analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide
covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and
The Adrenocortical Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for
Adrenocortical Carcinoma (Adrenal Cortex Cancer) and features dormant and discontinued projects. The guide covers therapeutics under
Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Discovery stages are 5 and 1
respectively for Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively for Adrenocortical
Adrenocortical Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university
websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the
most recent developments are captured on a real time basis.
Place a direct purchase order on this report at http://www.orbisresearch.com/contact/purchase/146138 .
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Adrenocortical Carcinoma (Oncology).
– The pipeline guide reviews pipeline therapeutics for Adrenocortical Carcinoma (Oncology) by companies and universities/research
institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery
and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive
licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Adrenocortical Carcinoma (Oncology) therapeutics and enlists all their major
and minor projects.
– The pipeline guide evaluates Adrenocortical Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target,
route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Adrenocortical Carcinoma (Oncology)
Request a sample Adrenocortical Carcinoma (Adrenal Cortex Cancer)-Pipeline Review, H2 2016 Report
Companies Mentioned in this report are :
Millendo Therapeutics, Inc.
Orphagen Pharmaceuticals, Inc.
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
Email ID: email@example.com